AstraZeneca: several positive results in cancer

(CercleFinance.com) - On Monday AstraZeneca reported positive results for several cancer studies at the annual congress of the European Society for Medical Oncology (ESMO), which is currently being held in Barcelona.


In particular, the biopharmaceutical group announced that its Enhertu antibody-drug conjugate, developed with Japan's Daiichi Sankyo, had demonstrated 'clinically significant' activity in the treatment of patients with HER2-positive metastatic breast cancer accompanied by brain metastases.

In this indication, a phase IIIb/IV study concluded with a progression-free survival rate of 61.6% at 12 months, the laboratory said.

AstraZeneca also reported that a Phase III trial showed that perioperative administration of Imfinzi reduced the risk of disease recurrence by 32%, and of death by 25%, after neo-adjuvant (pre-operative) chemotherapy in patients with muscle-invasive bladder cancer.

Finally, the monoclonal antibody Imfinzi combined with Imjudo, another of the company's anti-cancer agents, has enabled "unprecedented" survival of patients in a Phase III study, with one in five still alive after five years in advanced liver cancer.


Copyright (c) 2024 CercleFinance.com. All rights reserved.